Evaluation of intralesional administration of rituximab for treatment of orbital lymphoma - ND

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-007799-40-IT

Enrollment

Registered

2007-12-18

Start date

2008-01-28

Completion date

Unknown

Last updated

2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

orbital lymphoma MedDRA version: 9.1 Level: LLT Classification code 10003899 Term: B-cell lymphoma

Interventions

Trade Name: MABTHERA Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -primary diffuse large cell B cell Lymphoma / Follicular-centre cell lymphoma -expression of Antigen CD20 -ocular/periocular confined lesion Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: -other subtype of lymphomas than primary diffuse large cell B cell Lymphoma / Follicular-centre cell lymphoma -no expression of Ag CD20 -widespread diffusion of disease -age<18 -pregnancy -lactation -unstable cardiopathy

Design outcomes

Primary

Measure	Time frame
Main Objective: to evaluate the safety and efficacy of intralesional administration of a anti-CD20 monoclonal antibody (rituximab) for the treatment of patients affected by lymphomas CD20+ limited to ocular and peri-ocular localization.;Secondary Objective: nd;Primary end point(s): nd	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026